EMEA-002414-PIP01-18

Key facts

Active substance
Humanized anti-CD19, Fc engineered, monoclonal antibody (XmAb5871)
Therapeutic area
Immunology-Rheumatology-Transplantation
Decision number
P/0274/2019
PIP number
EMEA-002414-PIP01-18
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of immunoglobulin G4-related disease
Route(s) of administration
Subcutaneous use
Contact for public enquiries
Xencor, Inc.

E-mail: mlotz@xencor.com
Tel. +1 8584 803338

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating